blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3861001

EP3861001 - BORON CONTAINING PDE4 INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.10.2024
Database last updated on 31.03.2026
FormerThe patent has been granted
Status updated on  10.11.2023
FormerGrant of patent is intended
Status updated on  18.07.2023
FormerExamination is in progress
Status updated on  27.01.2023
FormerRequest for examination was made
Status updated on  09.07.2021
FormerThe international publication has been made
Status updated on  11.04.2020
Formerunknown
Status updated on  21.10.2019
Most recent event   Tooltip13.03.2026Lapse of the patent in a contracting state
New state(s): HU		published on 15.04.2026 [2026/16]
Applicant(s)For all designated states
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
[2023/14]
Former [2021/32]For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
Inventor(s)01 / STROHBACH, Joseph Walter
c/o Pfizer Inc.
610 Main Street
Cambridge, Massachusetts 02139 / US
02 / BLAKEMORE, David Clive
c/o Pfizer Inc.
445 Eastern Point Road, Bldg. 98
Groton, Connecticut 06340 / US
03 / JONES, Peter
10 Pine Road
Sharon, Massachusetts 02067 / US
04 / LIMBURG, David Christopher
c/o Pfizer Inc.
445 Eastern Point Road, Bldg. 98
Groton, Connecticut 06340 / US
05 / ODERINDE, Martins Sunday
1221 Wheldon Shivers Drive
Ewing, New Jersey 08628 / US
06 / TORELLA, Rubben Federico
c/o Pfizer Inc.
610 Main Street
Cambridge, Massachusetts 02139 / US
07 / YEOH, Thean Yeow
c/o Pfizer Inc.
445 Eastern Point Road, Bldg. 98
Groton, Connecticut 06340 / US
08 / AKAMA, Tsutomu
1-4-28-204 Ikenohata Taito-ku
Tokyo 110-0008 / JP
09 / JACOBS, Robert Toms
1849 Old College Circle
Wake Forest, North Carolina 27587 / US
10 / PERRY, Matthew Alexander
c/o Pfizer Inc.
445 Eastern Point Road, Bldg. 98
Groton, Connecticut 06340 / US
11 / PLATTNER, Jacob John
2873 NW Perlette Lane
Bend, Oregon 97703 / US
12 / ZHOU, Yasheen
62 Sanders Ranch Road
Moraga, California 94556 / US
 [2021/32]
Representative(s)Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
[2021/32]
Application number, filing date19782756.101.10.2019
[2021/32]
WO2019IB58355
Priority number, dateUS201862741868P05.10.2018         Original published format: US 201862741868 P
US201962889599P21.08.2019         Original published format: US 201962889599 P
[2021/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020070651
Date:09.04.2020
Language:EN
[2020/15]
Type: A1 Application with search report 
No.:EP3861001
Date:11.08.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 09.04.2020 takes the place of the publication of the European patent application.
[2021/32]
Type: B1 Patent specification 
No.:EP3861001
Date:13.12.2023
Language:EN
[2023/50]
Search report(s)International search report - published on:EP09.04.2020
ClassificationIPC:C07F5/02, A61P29/00, A61K31/69
[2021/32]
CPC:
A61P29/00 (EP,IL); A61K31/69 (IL,KR,US); C07F5/025 (EP,IL,KR,US);
A61K31/519 (IL,US); A61P17/00 (KR); C07F7/1804 (EP,IL);
C07B2200/13 (IL,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/32]
Extension statesBA06.05.2021
ME06.05.2021
Validation statesMA06.05.2021
MD06.05.2021
TN06.05.2021
TitleGerman:BORHALTIGE PDE4-INHIBITOREN[2021/32]
English:BORON CONTAINING PDE4 INHIBITORS[2021/32]
French:INHIBITEURS DE PDE4 CONTENANT DU BORE[2021/32]
Entry into regional phase06.05.2021National basic fee paid 
06.05.2021Designation fee(s) paid 
06.05.2021Examination fee paid 
Examination procedure06.04.2021Amendment by applicant (claims and/or description)
06.05.2021Examination requested  [2021/32]
06.05.2021Date on which the examining division has become responsible
26.01.2023Despatch of a communication from the examining division (Time limit: M04)
28.02.2023Reply to a communication from the examining division
19.07.2023Communication of intention to grant the patent
06.11.2023Fee for grant paid
06.11.2023Fee for publishing/printing paid
06.11.2023Receipt of the translation of the claim(s)
Opposition(s)16.09.2024No opposition filed within time limit [2024/47]
Fees paidRenewal fee
02.11.2021Renewal fee patent year 03
31.10.2022Renewal fee patent year 04
31.10.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY01.10.2019
HU01.10.2019
AT13.12.2023
CZ13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
MC13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
[2026/16]
Former [2026/10]CY01.10.2019
AT13.12.2023
CZ13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
MC13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
Former [2025/33]AT13.12.2023
CZ13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
MC13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
Former [2024/49]AT13.12.2023
CZ13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
Former [2024/36]AT13.12.2023
CZ13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
Former [2024/35]AT13.12.2023
CZ13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
RO13.12.2023
RS13.12.2023
SM13.12.2023
BG13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/34]EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
RS13.12.2023
SM13.12.2023
BG13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/33]HR13.12.2023
LT13.12.2023
LV13.12.2023
RS13.12.2023
SM13.12.2023
BG13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/32]HR13.12.2023
LT13.12.2023
LV13.12.2023
RS13.12.2023
BG13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/26]HR13.12.2023
LT13.12.2023
LV13.12.2023
RS13.12.2023
BG13.03.2024
GR14.03.2024
Former [2024/25]HR13.12.2023
LT13.12.2023
RS13.12.2023
BG13.03.2024
GR14.03.2024
Former [2024/21]LT13.12.2023
BG13.03.2024
GR14.03.2024
Former [2024/20]GR14.03.2024
Cited inInternational search[IA] US2009291917  (AKAMA TSUTOMU et al.)
 [A] WO2006089067  (ANACOR PHARMACEUTICALS INC et al.)
 [A]   TREVOR W. BUTCHER ET AL: "Regioselective Copper-Catalyzed Boracarboxylation of Vinyl Arenes", ORGANIC LETTERS, vol. 18, no. 24, 16 December 2016 (2016-12-16), US, pages 6428 - 6431, XP055640413, ISSN: 1523-7060, DOI: 10.1021/acs.orglett.6b03326

DOI:   http://dx.doi.org/10.1021/acs.orglett.6b03326
by applicantEP0901786
 US2002009494
   RAHMAN, INF. & ALL., vol. 10, 2011, pages 486
   EYERICHEYERICH, J. EUR. AC. DERM. VEN., vol. 32, 2018, pages 692
   WANG ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 234, 1997, pages 320
   TAKEUCHI, H. ET AL.: "Enhancement of the dissolution rate of a poorly water-soluble drug (tolbutamide) by a spray-drying solvent deposition method and disintegrants", J. PHARM. PHARMACOL., vol. 39, 1987, pages 769 - 773
   MERRITT ET AL.: "Diffusion Apparatus for Skin Penetration", J OF CONTROLLED RELEASE, vol. 1, 1984, pages 161 - 162, XP023843582, doi:10.1016/0168-3659(84)90010-5

DOI:   http://dx.doi.org/10.1016/0168-3659(84)90010-5
   "IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry", PURE APPL. CHEM., vol. XIV, 1976, pages 13 - 30
   S. M. BERGE ET AL.: "describe pharmaceutically acceptable salts in detail", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
   GOODMANGILMAN'S: "The Pharmacological Basis of Therapeutics", 1985, MACMILLAN PUBLISHING COMPANY
   LOUIS F. FIESERMARY FIESER: "Reagents for Organic Synthesis", vol. 1-19, 1967, WILEY
   T. W. GREENE: "Beilsteins Handbuch der organischen Chemie", 1991, JOHN WILEY & SONS
   TW GREENEPGM WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY AND SONS, INC.
   RC LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS INC.
   S WARREN: "Designing Organic Synthesis", 1978, WILEY INTERSCIENCE
   RK MACKIEDM SMITH: "Organic Synthesis - The Disconnection Approach", 1982, WILEY INTERSCIENCE
   PJ KOCIENSKI: "Protecting Groups", 1994, GEORG THIEME VERLAG
   THEODORA W GREENEPETER GM WUTS: "Greene's Protective Groups in Organic Synthesis", 2014, JOHN WILEY AND SONS
   CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 14447963-75-8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.